TOI Valuation

Oncology Institute Inc

Add to Watchlist

Advanced Chart

3.400

-0.08(-2.299%)1D

Overview
Forecast
Valuation
Earnings

TOI Relative Valuation

TOI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TOI is overvalued; if below, it's undervalued.

Historical Valuation

Oncology Institute Inc (TOI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.62 is considered Fairly compared with the five-year average of -5.63. The fair price of Oncology Institute Inc (TOI) is between 2.18 to 4.26 according to relative valuation methord.

Relative Value

Fair Zone

2.18-4.26

Current Price：3.42

Fair

-9.86

Trailing

Forward

-115.71

EV/EBITDA

Oncology Institute Inc. (TOI) has a current EV/EBITDA of -115.71. The 5-year average EV/EBITDA is -9.50. The thresholds are as follows: Strongly Undervalued below -64.58, Undervalued between -64.58 and -37.04, Fairly Valued between 18.03 and -37.04, Overvalued between 18.03 and 45.57, and Strongly Overvalued above 45.57. The current Forward EV/EBITDA of -115.71 falls within the Strongly Undervalued range.

-18.96

EV/EBIT

Oncology Institute Inc. (TOI) has a current EV/EBIT of -18.96. The 5-year average EV/EBIT is -6.09. The thresholds are as follows: Strongly Undervalued below -22.56, Undervalued between -22.56 and -14.33, Fairly Valued between 2.14 and -14.33, Overvalued between 2.14 and 10.37, and Strongly Overvalued above 10.37. The current Forward EV/EBIT of -18.96 falls within the Undervalued range.

0.62

Oncology Institute Inc. (TOI) has a current PS of 0.62. The 5-year average PS is 0.46. The thresholds are as follows: Strongly Undervalued below -0.90, Undervalued between -0.90 and -0.22, Fairly Valued between 1.15 and -0.22, Overvalued between 1.15 and 1.83, and Strongly Overvalued above 1.83. The current Forward PS of 0.62 falls within the Historic Trend Line -Fairly Valued range.

-48.52

P/OCF

Oncology Institute Inc. (TOI) has a current P/OCF of -48.52. The 5-year average P/OCF is -5.46. The thresholds are as follows: Strongly Undervalued below -23.53, Undervalued between -23.53 and -14.50, Fairly Valued between 3.57 and -14.50, Overvalued between 3.57 and 12.61, and Strongly Overvalued above 12.61. The current Forward P/OCF of -48.52 falls within the Strongly Undervalued range.

0.00

P/FCF

Oncology Institute Inc. (TOI) has a current P/FCF of 0.00. The 5-year average P/FCF is -2.84. The thresholds are as follows: Strongly Undervalued below -9.03, Undervalued between -9.03 and -5.94, Fairly Valued between 0.25 and -5.94, Overvalued between 0.25 and 3.34, and Strongly Overvalued above 3.34. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Oncology Institute Inc (TOI) has a current Price-to-Book (P/B) ratio of -36.13. Compared to its 3-year average P/B ratio of 3.55 , the current P/B ratio is approximately -1117.08% higher. Relative to its 5-year average P/B ratio of 2.74, the current P/B ratio is about -1418.46% higher. Oncology Institute Inc (TOI) has a Forward Free Cash Flow (FCF) yield of approximately -4.04%. Compared to its 3-year average FCF yield of -86.86%, the current FCF yield is approximately -95.35% lower. Relative to its 5-year average FCF yield of -70.32% , the current FCF yield is about -94.25% lower.

-35.30

P/B

Median3y

3.55

Median5y

2.74

-4.02

FCF Yield

Median3y

-86.86

Median5y

-70.32

Competitors Valuation Multiple

The average P/S ratio for TOI's competitors is 1.65, providing a benchmark for relative valuation. Oncology Institute Inc Corp (TOI) exhibits a P/S ratio of 0.62, which is -62.17% above the industry average. Given its robust revenue growth of 21.53%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TOI.O

Oncology Institute Inc

Performance Decomposition

Market capitalization of TOI increased by 863.99% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.53 to -5.05.

The secondary factor is the Revenue Growth, contributed 21.53%to the performance.

Overall, the performance of TOI in the past 1 year is driven by P/E Change. Which is more unsustainable.

21.53%

98.58M → 119.80M

Revenue Growth

-9.55%

-15.70 → -14.20

Margin Expansion

852.01%

-0.53 → -5.05

P/E Change

863.99%